Our Microbiome Drug Discovery and Development Platform utilizes the award-winning PhyloChip® assay developed by Dr. Gary Andersen at the Lawrence Berkeley National Laboratory. The PhyloChip® assay represents years of research and development resulting in what is now a mature technology capable of providing the most detailed measurements of microbial community dynamics in a high-throughput and reproducible manner.

Microbial communities found in human and environmental samples contain thousands of different microbial species. Typically, these communities include a few dominant organisms and a large number of microbes at very small overall abundance levels. These rare bugs can be important in driving vital processes and ecosystem function.

PhyloChip® assay is a high-throughput, microarray-based method that identifies and measures the relative abundance of more than 50,000 individual microbial taxa.

  • Unlike sequencing methods, PhyloChip® relies on the analysis of all nine variable regions of the 16S gene, providing more in-depth taxonomic classification than other common approaches. This gene is present in every bacterial genome but varies in a way that provides a fingerprint for specific microbial types.
  • PhyloChip® provides the ability to identify minority abundance community members and determine relative differences for these members, which sequencing technologies can miss.
  • With ~1 million probes per chip, the microarray-based hybridization approach ensures that measurements on important low abundance bacteria are not overwhelmed by commonplace, dominant microbial community members.
  • This platform also demonstrates the capabilities required to be considered for regulated applications, including high within-lab repeatability and between-lab reproducibility.

Second Genome has an exclusive right to this technology, making it the only platform with this high resolution analysis tool.